GSK to acquire potential multiple myeloma treatment from Chimagen Biosciences
GSK plc has entered an agreement to acquire a potential new treatment for multiple myeloma from Chimagen Biosciences. The drug is a novel T-cell engager (TCE) expected to enter clinical trials in 2027.
London, UK – September 15, 2026 – Pharmaceutical company GSK plc announced today it has agreed to acquire a potential multiple myeloma therapy from Chimagen Biosciences. The therapy is a trispecific T-cell engager (TCE) designed to target T cells and two tumor antigens. GSK plans to develop and commercialize the asset, with the program expected to enter Phase I clinical trials in 2027.
TCEs have shown efficacy in treating multiple myeloma, but often present tolerability challenges. Chimagen's trispecific TCE aims to overcome these by simultaneously binding to T cells and two specific tumor-associated antigens. This targeted approach is intended to achieve deeper and more durable responses with improved tolerability compared to existing TCEs, potentially allowing for broader adoption and earlier use in patient treatment.
The agreement includes an upfront payment and potential success-based development and commercial milestone payments, with a total potential value of up to $750 million. This acquisition aligns with GSK's strategy to expand its portfolio in blood cancers and acquire differentiated assets with validated targets.
Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases diagnosed each year. While treatable, it is not currently curable, making research into new therapies vital as the disease often becomes refractory to available treatments.